Device advice - Issue 2
Hospital medical devices newsletter
Your update on PHARMAC’s Hospital Medical Devices programme
Issue 2 - 9 October 2013
In this issue:
PHARMAC is holding an information-seeking consultation to help inform our next steps towards management of hospital medical devices. What we learn in this consultation will contribute not only to our devices work, but also to the wider review of PHARMAC’s operating policies and procedures.
The consultation will be held between 16 October and 29 November 2013.
We have been out speaking to a range of people in the sector and the next phase of our work will help us build on what we know.
The consultation will be broad ranging and open to anyone who wishes to respond. We’ll be seeking submissions that help us work out how we will apply the PHARMAC model to medical devices.
The first of our medical devices consultations (held in November last year) was specifically focused on what a clinical engagement framework might look like for when management begins. The current consultation is on a broader range of questions about other aspects we need to consider.
We recognise that a very wide range of people interact with medical devices in hospitals and that these interactions are different to medicines. In this consultation we’re keen to hear from people who have experience of the current system, about what PHARMAC needs to know as it works out how to apply its model to medical devices. Considerations could include, but are not limited to, economic assessment, prioritisation, an exceptions policy, contract management, and implementation issues for national management.
PHARMAC recognises that medical devices are not the same as medicines and that how we apply our operating policies and procedures must reflect this.
PHARMAC’s aim is to develop processes that improve national consistency in the treatment of patients, provide for appropriate variation where needed, and free up health spending that can then be re-invested in the health sector.
A set of guiding questions will be included in the consultation document to help provoke thought from submitters, but PHARMAC is keen to hear from anyone on any element of management of medical devices that they think needs our consideration.
This is an important opportunity to influence the policies and procedures that are established to support this work and PHARMAC encourages anyone with particular expertise and knowledge, or just an interest, in hospital medical devices to put forward a submission.
As part of the current consultation process, we will be hosting a series of open forums at DHB venues around the country. The more people we hear from, the more information we can gather to shape our work.
Anyone is welcome to attend one of the following forums:
22 October, 12pm – 2pm
Clinical Education Centre Auditorium
25 October, 12pm – 2pm
Ko Awatea Centre
30 October, 2pm – 4pm
Medical Lecture Theatre
Palmerston North Hospital
4 November, 12pm – 2pm
Small lecture theatre
Conference Centre, University of Otago Wellington School of Medicine
11 November, 2 pm – 4 pm
Oncology Lecture Theatre, Ground Floor, Oncology,
Christchurch Public Hospital
12 November, 10am – 12pm
Colquhoun Lecture Theatre
15 November, 12pm – 2pm
Bryant Education Centre
A copy of the consultation document, which will be released on 16 October, will be available online.
If you have any further questions about these forums or the consultation, please email: email@example.com or call Megan Whittleston on 04 901 3208.
As mentioned, what we learn in this medical devices consultation will contribute to PHARMAC’s overall review of its operating policies and procedures (OPPs).
PHARMAC has just completed the first round of consultation on another aspect of its OPPs – whether the decision criteria we use for determining which pharmaceuticals are available for public funding still reflect the things that the public feel are important.
The decision criteria consultation also seeks to ensure that as PHARMAC’s role expands, the existing decision criteria remain fit for purpose.
The decision criteria are relevant to medical devices management, which falls outside PHARMAC’s traditional focus on pharmaceuticals used in the community, cancer medicines used in hospitals and more recently, vaccines and hospital medicines.
We are now considering the responses to this consultation, and intend to run a second round of consultation on any proposed changes in early 2014.
Some of you may have provided input into both the medical devices clinical framework consultation and the Decision Criteria Review consultation.
It is not necessary to repeat information you have already given – everything you have provided in any of our consultations will be considered together to help inform PHARMAC’s next step towards medical devices management. However, we are still keen to hear from you on any additional points you want to raise.
PHARMAC will use the information we gain from this consultation to help form a proposal for how it might apply PHARMAC’s operating policies and procedures or management of medical devices.
We will consult on this proposal in the early part of next year. A summary of submissions to this consultation will also be published.
PHARMAC aims to have a functional framework for medical devices management in place by mid-2015, with the range of devices being actively managed by PHARMAC increasing over time.
This will be working towards full budget management, with a capped budget agreed by the Minister of Health and DHBs, sometime in the future.
The processes we develop will aim to extract the best health outcomes from within the available funding for hospital medical devices.
We are continuing to work alongside Health Benefits Limited (HBL), which is implementing a Finance, Procurement and Supply Chain Business Case in DHBs. Part of HBL’s work involves rolling out a National Product Catalogue and Financial Management Information System (FMIS) in DHBs. The Catalogue and FMIS are both key enablers for PHARMAC to take on management of hospital medical devices.
Many of you will be aware that HBL is coordinating a consultation process for those in the sector affected by the implementation of the Finance, Procurement and Supply Chain (FPSC) Business Case.
PHARMAC’s work is reliant on aspects of FPSC implementation and PHARMAC recognises the importance of alignment between its processes and those of the other organisations involved in this process. However, as we are not a service partner within the DHB shared service that HBL is establishing, we are not included within the scope of HBL’s consultation.
For more information on PHARMAC’s role in this process, please contact us.
PHARMAC is also continuing to talk to other organisations whose work intersects with ours, including healthAlliance, the National Health Committee (NHC) and the Ministry of Health.
As mentioned in our last newsletter, PHARMAC has begun an interim procurement process for a selection of medical device product categories, beginning in this financial year.
The basis of the Interim Procurement Project is to achieve some early savings for DHBs, through national procurement of a small group of items, before full management can begin. Essentially it will be looking to get the best price, for all DHBs, for particular items they are already using.
PHARMAC consulted on 11 categories identified for initial procurement activity and based on your feedback, we chose three categories for immediate procurement activity.
The first three categories are:
- Wound care
- Orthopaedic implants
We held a Registration of Interest process for suppliers of wound care products and received over 30 responses. Thank you to all those who took the time to participate in this process. We are currently evaluating the proposals and will be negotiating agreements with suppliers over the coming months.
We are also working with suppliers of sutures and orthopaedic implants to form similar agreements.
We will begin work on the eight other initial categories soon, however PHARMAC is happy to consider proposals from suppliers of any medical device products at any time.
Initially, the national agreements will be discretionary for DHBs to purchase from, with pricing listed on the Schedule. We will consult with clinicians and other stakeholders if this changes in the future.
For more details about how the interim procurement process will work, and important information about the first three categories and contracts.
We will regularly be updating all interested groups about the progress of the project.
Feel free to circulate this newsletter to anyone you think might be interested in this work – especially those who may wish to be involved in our upcoming consultation.
You are welcome to contact us directly at any time with proposals, suggestions or concerns.
Email us: firstname.lastname@example.org or give us a call: 04 460 4990
You can also find all of our medical devices information on our website.
If you want to stay in touch with the review of all PHARMAC’s Operating Policies and Procedures go to the web pages.
Last updated: 19 February 2019